{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"jRCT2031210311","nct_id":"NCT04586231","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jrct2031210311-nct04586231. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Belzutifan 120 mg and lenvatinib 20 mg orally once a day","label":"Belzutifan + Lenvatinib","type":"EXPERIMENTAL"},{"description":"Cabozantinib 60 mg orally once a day","label":"Cabozantinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eisai Inc."],"completion_date":{"date":"2027-02-11","type":"ESTIMATED"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":747,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["PT2977","MK-6482","WELIREG™"],"type":"DRUG"},{"name":"Lenvatinib","otherNames":["Lenvima","E7080","MK-7902"],"type":"DRUG"},{"name":"Cabozantinib","otherNames":["Cabometyx","Cometriq","XL184","BMS-907351"],"type":"DRUG"}],"last_update":"2026-05-05","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 34 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 44 months"}],"references":[{"citation":"Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 12:S0140-6736(26)01089-5. doi: 10.1016/S0140-6736(26)01089-5. Online ahead of print.","pmid":"42586114","type":"DERIVED"},{"citation":"Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.","pmid":"36752726","type":"DERIVED"}],"start_date":{"date":"2021-02-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","url":"https://clinicaltrials.gov/study/NCT04586231"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jrct2031210311-nct04586231"}